Equities analysts expect Catalent (NYSE:CTLT) to post $0.60 earnings per share (EPS) for the current fiscal quarter, Zacks Investment Research reports. Six analysts have provided estimates for Catalent’s earnings, with the lowest EPS estimate coming in at $0.58 and the highest estimate coming in at $0.64. Catalent reported earnings per share of $0.65 during the same quarter last year, which suggests a negative year-over-year growth rate of 7.7%. The company is scheduled to report its next quarterly earnings report on Monday, August 27th.
According to Zacks, analysts expect that Catalent will report full year earnings of $1.68 per share for the current year, with EPS estimates ranging from $1.64 to $1.73. For the next year, analysts anticipate that the company will post earnings of $1.90 per share, with EPS estimates ranging from $1.72 to $1.97. Zacks’ EPS calculations are an average based on a survey of research firms that cover Catalent.
Catalent (NYSE:CTLT) last posted its earnings results on Tuesday, May 1st. The company reported $0.41 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.35 by $0.06. Catalent had a net margin of 2.62% and a return on equity of 21.76%. The business had revenue of $627.90 million for the quarter, compared to analyst estimates of $610.47 million. During the same period last year, the business posted $0.38 EPS. Catalent’s revenue was up 17.9% compared to the same quarter last year.
CTLT has been the subject of a number of research reports. Zacks Investment Research raised shares of Catalent from a “hold” rating to a “buy” rating and set a $46.00 price target for the company in a report on Thursday, March 8th. Goldman Sachs initiated coverage on shares of Catalent in a report on Wednesday, January 24th. They issued a “buy” rating and a $50.00 price target for the company. Raymond James raised shares of Catalent from a “market perform” rating to an “outperform” rating and set a $48.00 price target for the company in a report on Wednesday, March 21st. They noted that the move was a valuation call. Royal Bank of Canada set a $48.00 price target on shares of Catalent and gave the company a “buy” rating in a report on Monday, February 5th. Finally, ValuEngine raised shares of Catalent from a “hold” rating to a “buy” rating in a report on Wednesday, February 7th. Five investment analysts have rated the stock with a hold rating and twelve have given a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average price target of $45.67.
Shares of Catalent opened at $40.20 on Friday, MarketBeat Ratings reports. The company has a quick ratio of 1.78, a current ratio of 2.18 and a debt-to-equity ratio of 2.53. Catalent has a fifty-two week low of $31.88 and a fifty-two week high of $47.87. The firm has a market capitalization of $5.36 billion, a price-to-earnings ratio of 24.97, a P/E/G ratio of 2.13 and a beta of 1.53.
In other news, SVP William Downie sold 9,082 shares of the firm’s stock in a transaction dated Thursday, March 8th. The shares were sold at an average price of $41.80, for a total transaction of $379,627.60. Following the completion of the transaction, the senior vice president now directly owns 46,986 shares of the company’s stock, valued at approximately $1,964,014.80. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 1.70% of the stock is currently owned by company insiders.
Several large investors have recently added to or reduced their stakes in CTLT. First Bank & Trust lifted its holdings in shares of Catalent by 54.2% during the 4th quarter. First Bank & Trust now owns 3,764 shares of the company’s stock worth $155,000 after acquiring an additional 1,323 shares during the period. CAPROCK Group Inc. bought a new position in shares of Catalent during the 4th quarter worth about $203,000. Quantbot Technologies LP bought a new position in shares of Catalent during the 1st quarter worth about $229,000. Her Majesty the Queen in Right of the Province of Alberta as represented by Alberta Investment Management Corp bought a new position in shares of Catalent during the 4th quarter worth about $242,000. Finally, Zeke Capital Advisors LLC bought a new position in shares of Catalent during the 1st quarter worth about $289,000.
Catalent Company Profile
Catalent, Inc provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products worldwide. It operates through three segments: Softgel Technologies, Drug Delivery Solutions, and Clinical Supply Services. The Softgel Technologies segment offers formulation, development, and manufacturing services for softgels, which are used in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, and unit-dose cosmetics.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Catalent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent and related companies with MarketBeat.com's FREE daily email newsletter.